copper sulfate has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviram, M; Hussein, O; Keidar, S; Rosenblat, M; Schlezinger, S | 1 |
1 other study(ies) available for copper sulfate and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Topics: Adult; Aged; Amidines; Anticholesteremic Agents; Copper Sulfate; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Humans; Hypercholesterolemia; Indoles; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Middle Aged | 1997 |